Pfizer reports final vaccine results: 95% efficacy

Enlarge / An illustration picture shows vials with Covid-19 Vaccine stickers attached, with the logo of US pharmaceutical company Pfizer, on November 17, 2020. (credit: Getty | JUSTIN TALLIS)

Pharmaceutical giant Pfizer and German biotech firm BioNTech announced Wednesday that they have wrapped up the Phase III trial of their COVID-19 mRNA vaccine, finding it to be 95 percent effective at preventing disease and consistently effective across age, gender, race, and ethnicity demographics. The vaccine appeared effective at preventing cases of severe disease as well.

The companies added that they have also met a safety milestone-collecting a median of two months of safety monitoring data on trial participants-to file a request for an Emergency Use Authorization (EUA) with the US Food and Drug Administration. They plan to file the request within days."

The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," Dr. Albert Bourla, Pfizer Chairman and CEO, said in a statement. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world."

Read 9 remaining paragraphs | Comments